Atrium Therapeutics clears IND for ATR 1072, activates first Corventis sites for PRKAG2 syndrome
The company also banked a second $15 million Bristol Myers Squibb milestone and reported cash runway into mid-2028.
Atrium Therapeutics reported second-quarter 2026 results on August 13, highlighting FDA clearance of its Investigational New Drug application for ATR 1072 and the start of site activities for its Corventis trial in PRKAG2 syndrome. The clearance allows the company to proceed with Corventis, described as a Phase 1/2 open-label, multicenter study looking at safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072 in people with PRKAG2 syndrome.1 Health Canada also issued a No Objection Letter, permitting activation of planned Corventis sites in Canada.1
The trial is designed to enroll about 37 participants across two parts: Part A will use multiple ascending dose cohorts to establish safety and guide dose selection, while Part B will be a single-arm expansion cohort at the chosen Phase 2 dose to look further at effects on cardiac structure and function.1 ATR 1072 marks Atrium's first precision cardiology candidate to reach clinical testing.1 The company has now begun clinical site activities for Corventis and still expects to enroll its first participant by the end of 2026.1 Atrium said it expects to report initial trial data demonstrating proof of concept in the second half of 2027.1
On the partnership side, Atrium reached a second milestone in August under its global cardiovascular collaboration with Bristol Myers Squibb, which triggers a $15 million payment to be recorded in third-quarter financial results.1
Looking ahead, the company plans to file an IND for ATR 1086 in 2027, with IND-enabling studies beginning in 2026, and is also advancing two undisclosed rare cardiomyopathy programs, aiming to select a next development candidate in 2027.1
On finances, Atrium held $263.9 million in cash, cash equivalents, and short-term investments as of June 30, 2026.1 The company said this total, including the August BMS milestone payment, should be sufficient to fund planned operations through mid-2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.